Investors presentation February 2017
Disclaimer 2 The information included in this presentation is a summary only and performance, or achievements to be materially different from those does not exhaust all of the information on the Company and its anticipated by the forward-looking statements. We discuss many of business, nor is it a substitute for inspection of the Periodic Report for these risks in the “ Risk Factors ” section and elsewhere in the 2015, the quarterly reports for 2016, the Company ’ s current reports Registration Statement on Form F-1 filed with the U.S. Securities and and the presentations released thereby, as reported to the ISA via the Exchange Commission and in the Periodical reports (in Hebrew) with Magna distribution site. The presentation does not constitute an the Israeli Security Authority and the Tel Aviv Stock Exchange. You offering or an invitation to purchase securities of the Company, and should not rely upon forward-looking statements as predictions of the provisions thereof do not constitute a recommendation or opinion future events. Although we believe that the expectations reflected in or substitute for the discretion of the investor. The Company is not the forward-looking statements are reasonable, we cannot guarantee responsible for the integrity or accuracy of the information. This future results, levels of activity, performance, or achievements. Except presentation includes forecasts, estimates, assessments and other as required by law, we are under no duty to update or revise any of information pertaining to future events and/or matters, whose the forward-looking statements, whether as a result of new materialization is uncertain and is beyond the Company ’ s control, and information, future events or otherwise, after the date of this which constitute forward-looking information, as defined in the prospectus. These forward-looking statements speak only as of the Securities Law, 5728-1968. Such information may not materialize, in date of this presentation, and we assume no obligation to update or whole or in part, or may materialize in a manner significantly different revise these forward-looking statements for any reason. to that forecast. Such information includes, inter alia, statements relating to our objectives, plans, and strategies; statements that The information presented was prepared according to the past contain projections of results of operations or of financial condition; experience and professional knowledge accumulated by the Company statements relating to the research, development, and use of our and in good faith. Such information is presented below for the sake of technologies, products and product candidates; and all statements convenience only, but is not a substitute for the information provided (other than statements of historical facts) that address activities, by the Company in its financial statements or its immediate reports or events, or developments that we intend, expect, project, believe, or in connection therewith, and therefore should not be relied on solely anticipate will or may occur in the future. Forward-looking statements in itself. are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on The information included in this presentation is similar to the assumptions and assessments made by our management in light of information included in the reports and/or immediate reports of the their experience and their perception of historical trends, current Company and does not include new material information. However, conditions, expected future developments, and other factors they some of the data included in the presentation are presented in a believe to be appropriate. Important factors that could cause actual different manner and/or breakdown and/or are differently edited. In results, developments, and business decisions to differ materially from any event of inconsistency between the reports and/or immediate those anticipated in these forward-looking statements include, among reports of the Company released to the public and the information other things: the overall global economic environment; the impact of contained in this presentation, the information released to the public competition and new technologies; general market, political, and as aforesaid shall prevail. economic conditions in the countries in which we operate; projected capital expenditures and liquidity; changes in our strategy; All figures are approximate. government regulations and approvals; litigation and regulatory proceedings. These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry ’ s actual results, levels of activity,
Overview 3 ● We are a regenerative medicine company focused on developing and commercializing products for the orthobiologics and wound care markets ● Our technology allows the cost-efficient production of high quality recombinant human collagen (rhCollagen) ● Our two lead products have received CE marking, and product launches across Europe have been initiated ● We entered into an agreement with Arthrex , a leading orthopedic company, for European distribution of VergenixSTR for the treatment of tendonitis ● We are co-developing a surgical matrix with Bioventus , a global leader in active orthopedic healing, to address a $1.8 billion opportunity in spinal surgery and trauma
Yehiel Tal Oded Shoseyov CEO Prof./Founder/CSO Experienced 4 • Regentis • Pauli Clean Tech • CBD Tech. Biomaterials management team • ProChon Biotech • Fulcrum-SPD • Kulicke & Soffa • Melodea Industries • Hebrew University Eran Rotem Ilan Belzer Nadav Orr, PhD CFO COO VP R&D • Tefron, CFO • BioHarvest • Ethicon (NYSE,TASE) Biosurgery, • Procognia Ltd. • Healthcare Tech., • Omrix Johnson & CFO (NASDAQ) Biopharmaceuticals Johnson &Gamida, CFO • Interpharm • E&Y Shomrat Shurtz Philippe VP Commercialization Bensimon VP RA/QA/CA • Protalix • BBDO Proximity • Maquet-Getinge • Clal holdings • 3M Medical
Our products 5 5 Orthopedics Wound care Surgical Matrix Soft Tissue Repair Matrix Wound Filler Spine fusion & trauma Tendinopathy Chronic & surgical wounds $1.8B $3.0B $2.0B Annual market potential
Pipeline with multiple value drivers 6 Annual Stage of development Product Field Indications market Upcoming milestones Commercialization candidate Discovery Preclinical Clinical Regulatory potential Pre-IDE submission for Chronic & Europe Wound care surgical $3.0B Surgical Wounds wounds indication US Commercialization in Europe Tendonitis $2.0B Orthobiologics EU with Arthrex Pre-IDE submission US CollPlant Spine fusion & IND submission (FDA) $1.8B Orthobiologics US Surgical Matrix trauma by Bioventus Cornea & BioInk 3D Bioprinting cardiac patch Wholly-Owned Partnered
Recent accomplishments and planned upcoming milestones 7 Recent accomplishments: ● Initial distributors established for VergenixFG and sales commenced ● Positive clinical results of VergenixSTR ● VergenixSTR CE mark received ● VergenixSTR distribution agreement with Arthrex for pan-European sales ● Commenced sales of VergenixSTR Planned upcoming milestones: ● Sign Definitive agreement with Bioventus * ● Successful EU market launch of VergenixSTR (with Arthrex) ● Expansion of VergenixFG distribution network from 2 to 6 territories in EU ● Completion of EU P ost M arketing S urveillance study with VergenixFG (50 subjects) ● Initiate FDA process (e.g. pre-IDE meeting) with VergenixSTR ● Signing new co-development agreement with a partner (e.g. BioInk, Orthopedics) * While the co-development activity is ongoing, no license and supply agreement has been entered into and there can be no assurance that we will enter into any definitive agreement with Bioventus. In anticipation of filing an IND, Bioventus is undertaking preclinical animal studies comparing the Collplant Surgical Matrix to other active comparators, and could decide to move forward with a competing product
CollPlant ’ s technology: cost effective and scalable production 8 Plant Leaves Protein Concentrate Collagen PLANTLETS PURIFICATION END PRODUCT GROWING EXTRACTION IN NURSERY & FILLING FABRICATION Low cost scalable Clean room facility Low cost space seed propagation
kit 9 PRP collection tube from any commercial PRP Kit Plasma Platelet-Rich Plasma Red Blood Cells
- Significant potential advantages over SoC Clinical trial results 10 Study results Study Design Study Results ● Single arm study 74% of patients show clinical success at 3M ● 40 patients with tennis elbow (tendinopathy) 86% of patients show clinical success at 6M ● One single treatment ● 3- and 6-month follow up ● End points – Safety; recovery in pain and motion as measured through PRTEE, Quality of Life questionnaire and grip strength test 6M 3M 86% 74% 3M 48% 6M 36%
Future opportunity for VergenixSTR 11 11 Tendon repair - injectable rhCollagen/PRP matrix intended for treatment of partial or full tendon tears ● Based on VergenixSTR technology ● Annual US incidents: ~400K ● RCR 1 , ACL 2 , Achilles 3 rhCollagen-PRP clot 1. http://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-15-4 2. http://orthosurg.ucsf.edu/patient-care/divisions/sports-medicine/conditions/knee/anterior-cruciate-ligament-injury-acl/ 3. http://www.uptodate.com/contents/achilles-tendinopathy-and-tendon-rupture
Recommend
More recommend
